EFG Asset Management North America Corp. Has $6.67 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• EFG Asset Management North America Corp. reduced its stake in Alnylam Pharmaceuticals by 7.3% in Q1, selling 1,955 shares and now holds 24,691 shares valued at approximately $6.67 million.
• Multiple institutional investors increased their holdings in Alnylam Pharmaceuticals, with Vanguard Group growing its position by 2.5% and Adage Capital Partners increasing theirs by 203.2% during the same period.
• Analysts have set a consensus rating of "Moderate Buy" for Alnylam Pharmaceuticals, with an average price target of $412.79, reflecting positive sentiment toward the company’s growth prospects.

EFG Asset Management North America Corp. decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 24,691 shares of the biopharmaceutical company's stock after selling 1,955 shares during the period. Alnylam Pharmaceuticals comprises 1.1% of EFG Asset Management North America Corp.'s portfolio, making the stock its 13th biggest position. EFG Asset Management North America Corp.'s holdings in Alnylam Pharmaceuticals were worth $6,669,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ALNY. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $243,000. Comerica Bank lifted its stake in Alnylam Pharmaceuticals by 631.7% in the 4th quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company's stock valued at $3,292,000 after acquiring an additional 12,079 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $612,000. Captrust Financial Advisors lifted its stake in Alnylam Pharmaceuticals by 32.7% in the 4th quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company's stock valued at $1,509,000 after acquiring an additional 1,581 shares in the last quarter. Finally, Brevan Howard Capital Management LP lifted its stake in Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 44 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

ALNY has been the topic of several research reports. Piper Sandler boosted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Barclays upped their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Bank of America upped their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. Jefferies Financial Group upped their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Finally, Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $417.38.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the transaction, the executive vice president directly owned 22,719 shares of the company's stock, valued at $10,297,841.13. This represents a 5.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 1,455 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. This trade represents a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,594 shares of company stock worth $25,551,456 in the last quarter. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $3.03 during trading hours on Monday, reaching $455.03. The company's stock had a trading volume of 925,938 shares, compared to its average volume of 958,623. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $469.81. The company's 50-day moving average is $387.47 and its 200-day moving average is $310.11. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $59.65 billion, a PE ratio of -184.22 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the business earned ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.